Retrospective Study on the Incidence and Management of Anemia in Oncology

Study Overview
=================
Brief Summary
-----------------
The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Official Title
-----------------
Retrospective Study on the Incidence and Management of Anemia in Oncology

Conditions
-----------------
Anemia, Cancer

Intervention / Treatment
-----------------
* Other: anemia assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old, Follow-up for cancer justifying hospitalization, Presenting anemia defined by a hemoglobin level <11 g / dL, Patient not having objected to the collection of his data after oral and written information. Exclusion Criteria: patients with a hemoglobin level ≥ 11 g / dL, adult patients under guardianship, curatorship or deprived of liberty, pregnancy or breast-feeding in progress at the time of hospitalization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| period 2011<br> | Other: anemia assessment<br>* evaluation of anemia status<br>|
| period 2018<br> | Other: anemia assessment<br>* evaluation of anemia status<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of anemia | number of patient with anemia (<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of transfusion prescriptions | number of transfusions performed on the number of patients hospitalized over the period | 2 years | 
| Assessment of erythropoiesis stimulating agents (EPO) prescriptions | number of prescriptions for erythropoiesis stimulating agents (EPO) | 2 years | 
| Assessment of iron prescriptions | number of prescriptions of iron (oral and intravenous) | 2 years | 
| Time between last transfusion and date of death | Delay between the date of the last transfusion and the date of patient's death | 2 years | 
| overall survival | Delay between the enrollment date and the date of patient's death | 2 years |